Consensus Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2026-02-09 pm EST			5-day change	1st Jan Change
60.77 ^USD	-1.97%		+8.73%	+12.66%

08:07am	AstraZeneca's Evinova Enters Clinical Development AI Partnership Deal	MT
Feb. 06	Wells Fargo Adjusts Bristol-Myers Squibb PT to $60 From $55, Maintains Equal Weight Rating	MT

Evolution of the Average Target: Bristol-Myers Squibb Company

Evolution of the Target Price: Bristol-Myers Squibb Company

Changes in Analyst Recommendations: Bristol-Myers Squibb Company

dad0e7b2f17a4d8.Lq4ZIupHmdQmsi64wNeC0LMtXhxQ4HSyZo5BKHEeqkI.RfovUYF_qqFQ8H-O-aLx4Mkda3FhiU3zV8AsWRV_-y0Z2nh1jhXMgk_afw~10d35372b9424f1f5deb6c09db618c10

Analysts' recommendations: Bristol-Myers Squibb Company

Feb. 06	Wells Fargo Adjusts Bristol-Myers Squibb PT to $60 From $55, Maintains Equal Weight Rating	MT
Feb. 06	Citigroup Adjusts Bristol-Myers Squibb PT to $64 From $60, Maintains Neutral Rating	MT
Feb. 06	JPMorgan Adjusts Bristol-Myers Squibb PT to $67 From $65, Maintains Overweight Rating	MT
Feb. 06	Morgan Stanley Lifts Price Target on Bristol-Myers Squibb to $40 From $37, Keeps Underweight Rating	MT
Feb. 06	Goldman Sachs Adjusts Price Target on Bristol-Myers Squibb to $61 From $57, Maintains Neutral Rating	MT
Feb. 06	Leerink Partners Adjusts Price Target on Bristol-Myers Squibb to $67 From $60, Maintains Outperform Rating	MT
Feb. 06	Guggenheim Raises Price Target on Bristol-Myers Squibb to $72 From $62, Maintains Buy Rating	MT
Feb. 05	JPMorgan Raises Bristol-Myers Squibb Price Target to $67 From $65	MT
Jan. 29	TD Cowen Adjusts Bristol-Myers Squibb Price Target to $60 From $54, Maintains Hold Rating	MT
Jan. 28	Piper Sandler Adjusts Bristol-Myers Squibb Price Target to $66 From $62, Maintains Overweight Rating	MT
Jan. 27	Citigroup Adjusts Price Target on Bristol-Myers Squibb to $60 From $53, Maintains Neutral Rating	MT
Jan. 26	BMO Capital Adjusts PT on Bristol-Myers Squibb to $55 From $47, Maintains Market Perform Rating	MT
Jan. 13	Leerink Partners Adjusts Price Target on Bristol-Myers Squibb to $60 From $54, Maintains Outperform Rating	MT
Jan. 09	Scotiabank Adjusts Price Target on Bristol-Myers Squibb to $60 From $53, Maintains Sector Perform Rating	MT
Jan. 07	UBS Upgrades Bristol-Myers Squibb to Buy From Neutral, Lifts Price Target to $65 From $46	MT
Dec. 17	Deutsche Bank Adjusts Price Target on Bristol-Myers Squibb to $65 From $52, Maintains Hold Rating	MT
Dec. 15	Sector Update: Health Care	MT
Dec. 15	Bristol-Myers Squibb Seen as Attractive Ahead of 2026 Pipeline Catalysts, BofA Says	MT
Dec. 15	BofA Securities Upgrades Bristol-Myers Squibb to Buy From Neutral, $61 Price Target	MT
Dec. 12	Morgan Stanley Adjusts Bristol-Myers Squibb PT to $37 From $36, Maintains Underweight Rating	MT
Dec. 10	HSBC Adjusts Price Target on Bristol-Myers Squibb to $53 From $50, Maintains Hold Rating	MT
Dec. 10	Wells Fargo Adjusts Price Target on Bristol-Myers Squibb to $55 From $53, Maintains Equalweight Rating	MT
Dec. 04	Scotiabank Adjusts Price Target on Bristol-Myers Squibb to $53 From $45, Maintains Sector Perform Rating	MT
Dec. 03	Sector Update: Health Care Stocks Higher Late Afternoon	MT
Dec. 01	Goldman Sachs Adjusts Price Target on Bristol-Myers Squibb to $57 From $51, Maintains Neutral Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	BRISTOL-MYERS SQUIBB COMPANY					-3.35%
	ELI LILLY AND COMPANY					+12.57%
	JOHNSON & JOHNSON					-3.64%
	ABBVIE INC.					+9.8%
	ROCHE HOLDING AG					-1.43%
	MERCK & CO., INC.					-0.54%
	ASTRAZENECA PLC					+9.11%
	NOVARTIS AG					-5.26%
	NOVO NORDISK A/S					+30.61%
	AMGEN INC.					-11.03%
	Average					+3.68%
	Weighted average by Cap.					+4.78%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

61.99USD

Average target price

59.91USD

Spread / Average Target

-3.35%

High Price Target

72.00USD

Spread / Highest target

+16.15%

Low Price Target

40.00USD

Spread / Lowest Target

-35.47%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Wells Fargo Securities
Citigroup
JPMorgan Chase
Morgan Stanley
Goldman Sachs
Leerink Partners
Guggenheim
TD Cowen
Piper Sandler
BMO Capital
Scotiabank
UBS
Deutsche Bank Securities
BofA Securities
HSBC
Daiwa Securities
Cantor Fitzgerald
Rothschild & Co Redburn
Berenberg Bank
Redburn Atlantic
Jefferies & Co.
Truist Securities
Bernstein
Barclays
Wolfe Research
Societe Generale
Redburn
William Blair & Co.
Credit Suisse
Atlantic Equities
Raymond James
Argus